Sermorelin: GHRH(1-29) Research Peptide Guide
Written by NorthPeptide Research Team | Reviewed December 18, 2025
What Is Sermorelin?
Sermorelin, also known as sermorelin acetate or GRF(1-29)NH2, is a synthetic peptide analog of human growth hormone-releasing hormone (GHRH). It consists of the first 29 amino acids of the naturally occurring 44-amino acid GHRH sequence, representing the shortest fragment that retains full biological activity at the GHRH receptor.
The peptide was developed in the 1980s following the isolation and characterization of endogenous GHRH. Researchers identified that the N-terminal 29-residue segment of GHRH was both necessary and sufficient for receptor binding and signal transduction, making it a practical and cost-effective research tool compared to full-length GHRH.
In 1997, sermorelin received FDA approval under the brand name Geref for diagnostic evaluation and treatment of idiopathic growth hormone deficiency in children. The product was voluntarily discontinued in 2008 by its manufacturer for commercial reasons — not due to safety concerns or regulatory action. This distinction is important context for researchers, as the compound’s pharmacological profile remains well-documented in the literature.
Today, sermorelin is widely used in research settings to study the somatotropic axis, pituitary function, and growth hormone secretion dynamics. It remains a reference compound in GHRH receptor pharmacology and continues to appear in published studies investigating growth hormone physiology.
Explore NorthPeptide's research-grade Sermorelin — verified ≥98% purity with full COA documentation. View product details and COA →
Molecular Structure and Amino Acid Sequence
Sermorelin corresponds to the first 29 amino acids of endogenous GHRH, with a C-terminal amide modification. Its full amino acid sequence is:
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
The molecular formula is C149H246N44O42S, with a molecular weight of approximately 3,357.9 Da.
Why GHRH(1-29) Retains Full Activity
Structure-activity studies conducted in the 1980s and 1990s demonstrated that the N-terminal region of GHRH — specifically residues 1 through 29 — contains all of the structural elements required for high-affinity binding to the GHRH receptor (GHRHR). The amino acids beyond position 29 in the full 44-residue sequence contribute primarily to metabolic stability rather than receptor recognition.
Key structural features of the 1-29 fragment include:
- Residues 1-6 form the binding domain critical for GHRHR activation. Modifications to this region, particularly at positions 1 (Tyr) and 2 (Ala), substantially reduce biological activity.
- Residues 6-29 adopt an amphiphilic alpha-helical conformation that stabilizes the peptide-receptor interaction.
- The C-terminal amidation (NH2) enhances metabolic stability compared to the free-acid form.
Compared to full-length GHRH(1-44), sermorelin has been shown in receptor binding assays to exhibit equivalent potency at the GHRHR while being more practical to synthesize. This makes it the standard research tool for studying GHRH receptor pharmacology.
Mechanism of Action
Sermorelin’s mechanism of action mirrors that of endogenous GHRH, working through a well-characterized signaling cascade at the anterior pituitary gland.
GHRH Receptor Binding and Somatotroph Stimulation
Sermorelin binds to the GHRH receptor, a G protein-coupled receptor (GPCR) expressed on somatotroph cells of the anterior pituitary. Upon binding, the receptor activates adenylyl cyclase via the Gs alpha subunit, increasing intracellular cyclic AMP (cAMP) levels. This cAMP elevation triggers protein kinase A (PKA) activation, which opens voltage-gated calcium channels and promotes the exocytosis of stored growth hormone (GH) granules.
Importantly, this process stimulates GH release in a pulsatile pattern that reflects the natural rhythm of GH secretion. This stands in contrast to exogenous recombinant GH administration, which delivers a bolus of GH that bypasses normal regulatory feedback. Research has investigated whether this pulsatile release pattern may be significant for downstream signaling, as GH receptor responsiveness has been observed to vary with pulse frequency and amplitude in animal studies.
Somatostatin Feedback Regulation
One of the most studied features of sermorelin’s pharmacology is that its effects are subject to somatostatin-mediated negative feedback. When GH levels rise following GHRH receptor activation, hypothalamic somatostatin release increases, which in turn suppresses further GH secretion from the pituitary. This creates a self-limiting physiological brake that has been investigated as a key difference between GHRH-stimulated GH release and direct exogenous GH administration.
Research suggests that this feedback mechanism means sermorelin-stimulated GH release has an inherent ceiling effect — the somatostatin response prevents excessive GH elevation, keeping levels within physiological ranges. This regulatory feature has been a focus of studies examining the safety profile of GHRH agonists compared to exogenous GH (Walker, 2006, PMC2699646).
Pituitary Reserve Preservation
Beyond acute GH release, sermorelin has been investigated for its effects on pituitary somatotroph function over time. Studies have suggested that GHRH receptor agonism may upregulate human growth hormone (hGH) mRNA transcription, potentially supporting the maintenance of pituitary GH-producing capacity. This has been studied in the context of age-related decline in GH secretion (somatopause), where pituitary GH reserves progressively diminish (Walker, 2006, PMC2699646).
Research Findings: Growth Hormone and IGF-1
Sermorelin has been the subject of numerous published studies examining its effects on the GH/IGF-1 axis. Below is a summary of key findings from the peer-reviewed literature.
GH Secretion in Aged Subjects
In a controlled study by Corpas et al., long-term administration of GHRH(1-29)NH2 to age-advanced men and women was associated with an approximately 82% increase in mean GH concentration and an approximate 28% elevation in IGF-1 levels. The study also observed a mean increase in lean body mass of approximately 1.26 kg in the treatment group (Corpas et al., 1997, PMID: 9141536).
These findings have been cited as evidence that GHRH receptor agonism can stimulate endogenous GH production even in subjects with age-related declines in GH secretion, though the researchers noted variability in individual responses.
Gender-Differentiated Responses
Research has indicated that GH responses to GHRH stimulation may differ between male and female subjects. Some studies have observed higher baseline GH levels and more robust GHRH-stimulated GH release in females, a phenomenon attributed to estrogen’s modulatory effects on pituitary GH secretion. Researchers have emphasized the importance of controlling for sex and gonadal steroid status in sermorelin studies.
Sleep Architecture and GH Release
The relationship between GHRH signaling and sleep has been investigated in animal models. Obal and Krueger demonstrated that inhibition of GHRH signaling suppressed both slow-wave sleep and GH secretion in rats, suggesting a link between GHRH activity, sleep architecture, and the nocturnal GH pulse (Obal & Krueger, 1991, PMID: 1747749). This line of research has implications for understanding the role of GH-releasing peptides in sleep-related research models.
Sermorelin in Research Models
Beyond its effects on the GH/IGF-1 axis, sermorelin has been utilized in several distinct research contexts.
Diagnostic Testing for GH Deficiency
Sermorelin has been studied extensively as a diagnostic agent for evaluating pituitary GH reserve. The sermorelin stimulation test — in which sermorelin is administered and subsequent GH levels are measured — has been investigated as a method for differentiating between hypothalamic and pituitary causes of GH deficiency. This application was one of the original FDA-approved indications for the compound (Kerrigan & Rogol, 2007, PMID: 18031173).
Pediatric GH Deficiency Studies
Thorner et al. studied the effects of once-daily subcutaneous GHRH(1-29) administration in GH-deficient children and reported accelerated growth rates, as measured by height velocity. The study suggested that chronic GHRH receptor stimulation could enhance endogenous GH production in the developing pituitary (Thorner et al., 1996, PMID: 8772599). These findings contributed to the clinical literature on GHRH agonists in pediatric endocrinology research.
Aging and Somatopause Research
The age-related decline in GH secretion — termed the somatopause — has been a major research focus for GHRH agonists. Walker’s comprehensive review in Clinical Interventions in Aging examined the rationale for studying sermorelin in this context, highlighting that GHRH receptor agonism preserves the physiological feedback mechanisms that regulate GH levels, unlike exogenous GH replacement (Walker, 2006, PMC2699646).
Glioma Research
A 2021 study by Pei et al. identified potential anti-proliferative activity of sermorelin in glioma cell models. The researchers observed that sermorelin treatment was associated with reduced proliferation in glioma cell lines and suggested it as a compound warranting further investigation in this context. While preliminary, this study represents an emerging area of sermorelin research beyond the somatotropic axis (Pei et al., 2021, PMID: 33842627).
In Vitro Receptor Binding Studies
Sermorelin remains a standard reference agonist in GHRH receptor pharmacology. It is used in radioligand binding assays, cAMP accumulation assays, and calcium flux measurements to characterize GHRHR function, screen novel GHRH analogs, and study receptor desensitization kinetics.
Sermorelin vs. Other GHRH/GHS Peptides
Researchers working with growth hormone secretagogues often need to compare the properties of different peptides. The following table summarizes key differences between sermorelin and other commonly studied GHRH/GHS peptides.
| Peptide | Receptor Target | Mechanism | Half-Life | Key Research Context |
|---|---|---|---|---|
| Sermorelin | GHRH receptor (GHRHR) | GHRH agonist; stimulates pulsatile GH release | 11-12 minutes | GHRH receptor pharmacology, GH deficiency diagnostics, somatopause |
| CJC-1295 (no DAC) | GHRH receptor (GHRHR) | Modified GHRH analog with enhanced stability | ~30 minutes | Extended GHRH signaling, sustained GH elevation studies |
| CJC-1295 (with DAC) | GHRH receptor (GHRHR) | Albumin-binding GHRH analog | 6-8 days | Long-acting GH secretagogue research, sustained IGF-1 elevation |
| Ipamorelin | Ghrelin receptor (GHS-R1a) | Selective ghrelin mimetic; stimulates GH via ghrelin pathway | ~2 hours | Selective GH release without cortisol/prolactin elevation |
| Tesamorelin | GHRH receptor (GHRHR) | Stabilized GHRH analog (trans-3-hexenoic acid modification) | 26-38 minutes | Visceral adiposity research, HIV-associated lipodystrophy |
| Hexarelin | Ghrelin receptor (GHS-R1a) | Potent ghrelin mimetic | ~70 minutes | GH secretion studies; also investigated for cardiac effects |
Key Distinctions
Receptor pathway: Sermorelin, CJC-1295, and tesamorelin all act through the GHRH receptor, while https://northpeptide.com/products/ipamorelin and hexarelin work through the ghrelin receptor (GHS-R1a). These represent two distinct pathways for stimulating GH release, and research has investigated combination protocols using peptides from both pathways to study potential synergistic effects on GH secretion.
Half-life: Sermorelin’s short half-life of 11-12 minutes contrasts sharply with https://northpeptide.com/products/cjc-1295-no-dac’s extended duration (especially the DAC-modified form at 6-8 days). This difference affects experimental design: sermorelin is suited for studying acute GH pulses and pituitary responsiveness, while longer-acting analogs are studied for sustained GH axis activation.
Selectivity: Research has noted that ipamorelin demonstrates selective GH release without significant effects on cortisol, prolactin, or ACTH levels. Sermorelin similarly shows a relatively clean GH-selective profile through its physiological GHRH pathway, though the mechanisms of selectivity differ between GHRH-receptor and ghrelin-receptor agonists.
Technical Specifications for Researchers
The following specifications are relevant for researchers working with sermorelin in laboratory settings.
| Parameter | Value |
|---|---|
| Chemical Name | Sermorelin acetate / GRF(1-29)NH2 |
| Molecular Formula | C149H246N44O42S |
| Molecular Weight | ~3,357.9 Da |
| Amino Acid Length | 29 residues |
| Half-Life | 11-12 minutes (IV and SC administration in research models) |
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water, bacteriostatic water, and sterile saline |
Storage and Stability
- Lyophilized (unreconstituted): Store at 2-8°C (refrigerated). Lyophilized sermorelin is generally stable for extended periods under refrigeration when kept sealed and protected from moisture.
- Reconstituted: Store at 2-8°C. Reconstituted solutions are typically stable for 30-90 days when refrigerated, though researchers should verify stability for their specific experimental conditions.
- Avoid: Repeated freeze-thaw cycles, exposure to direct light, temperatures above 25°C for extended periods.
Reconstitution Guidelines
- Allow the lyophilized vial to reach room temperature before opening.
- Add bacteriostatic water slowly along the inside wall of the vial.
- Swirl gently until fully dissolved. Do not shake — vigorous agitation can damage peptide structure.
- Once dissolved, the solution should be clear and free of particulates.
- Store reconstituted vial upright at 2-8°C.
Purity Considerations
Research-grade sermorelin should be characterized by HPLC purity (typically ≥98%) and confirmed by mass spectrometry. Certificate of analysis documentation, including HPLC chromatograms and MS data, is essential for ensuring experimental reproducibility. Researchers should verify peptide identity and purity before use in sensitive assays. https://northpeptide.com/products/sermorelin
Frequently Asked Questions
What is sermorelin used for in research?
Sermorelin is used in research to study the GHRH receptor, pituitary GH secretion dynamics, the somatotropic axis, and age-related changes in GH production. It serves as a reference GHRH agonist in receptor pharmacology studies and has been used in diagnostic protocols for evaluating pituitary GH reserve.
How does sermorelin differ from synthetic HGH?
Sermorelin stimulates the body’s own pituitary gland to produce and release growth hormone in a pulsatile, physiologically regulated pattern. Synthetic HGH (recombinant somatotropin) is exogenous GH administered directly, bypassing pituitary regulation and somatostatin feedback. Research has investigated whether this distinction has implications for the pattern and regulation of GH signaling.
What is sermorelin’s half-life?
Sermorelin has a short half-life of approximately 11-12 minutes following both intravenous and subcutaneous administration in research models. This short duration reflects rapid enzymatic degradation, particularly by dipeptidyl peptidase IV (DPP-IV), and is a key consideration in research protocol design.
Can sermorelin be combined with other peptides in research?
Published studies have investigated the combination of GHRH agonists (such as sermorelin) with ghrelin receptor agonists (such as https://northpeptide.com/products/ipamorelin or GHRP-6). Research suggests that GHRH and ghrelin-pathway peptides may produce synergistic effects on GH release when co-administered, as they act through distinct receptor pathways that converge on pituitary somatotrophs.
How should sermorelin be stored?
Lyophilized sermorelin should be stored refrigerated at 2-8°C. Once reconstituted in bacteriostatic water, it should remain refrigerated and is generally considered stable for 30-90 days. Avoid repeated freeze-thaw cycles and prolonged exposure to room temperature or light.
Is sermorelin FDA approved?
Sermorelin was FDA-approved in 1997 (as Geref) for the diagnostic evaluation and treatment of idiopathic GH deficiency in children. The product was voluntarily discontinued by its manufacturer in 2008 for commercial reasons, not due to safety or efficacy concerns. Sermorelin is currently available as a research peptide.
What is the difference between sermorelin and CJC-1295?
Both sermorelin and https://northpeptide.com/products/cjc-1295-no-dac act on the GHRH receptor, but they differ in half-life and duration of action. Sermorelin (11-12 minute half-life) produces acute, short-duration GH pulses, while CJC-1295 (especially the DAC-modified form with a 6-8 day half-life) produces sustained GH elevation. CJC-1295 achieves its extended duration through structural modifications that resist enzymatic degradation and, in the DAC form, through albumin binding.
References
- Walker RF. “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?” Clin Interv Aging. 2006;1(4):307-14. PMC2699646
- Corpas E et al. “Endocrine and metabolic effects of long-term administration of GHRH(1-29)NH2 in age-advanced men and women.” J Clin Endocrinol Metab. 1997. PMID: 9141536
- Thorner MO et al. “Once daily subcutaneous GHRH therapy accelerates growth in GH-deficient children.” J Clin Endocrinol Metab. 1996. PMID: 8772599
- Kerrigan JR, Rogol AD. “Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.” Paediatr Drugs. 2007;9(3). PMID: 18031173
- Pei Z et al. “A potentially effective drug for patients with recurrent glioma: sermorelin.” Ann Transl Med. 2021. PMID: 33842627
- Obal F Jr, Krueger JM. “Inhibition of growth hormone-releasing factor suppresses both sleep and growth hormone secretion in the rat.” Neuroendocrinology. 1991. PMID: 1747749
Written by NorthPeptide Research Team
Ready to explore research-grade peptides?
Research Disclaimer
This article is provided for informational and educational purposes only. All peptides sold by NorthPeptide are intended for laboratory and research use only. Not for human consumption. Nothing in this article should be construed as medical advice or as a claim that sermorelin treats, cures, or prevents any disease or medical condition. Researchers should consult relevant institutional guidelines and regulatory requirements before conducting any studies. The research findings discussed herein are drawn from published peer-reviewed literature and are presented for reference purposes only.